- Home
- PRME vs ORGO Comparison
PRME vs ORGO Comparison
Compare PRME & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRME
- ORGO
- Stock Information
- Founded
- PRME 2019
- ORGO 1985
- Country
- PRME United States
- ORGO United States
- Employees
- PRME N/A
- ORGO N/A
- Industry
- PRME Medicinal Chemicals and Botanical Products
- ORGO Biotechnology: Pharmaceutical Preparations
- Sector
- PRME Health Care
- ORGO Health Care
- Exchange
- PRME Nasdaq
- ORGO Nasdaq
- Market Cap
- PRME 693.5M
- ORGO 620.3M
- IPO Year
- PRME 2022
- ORGO N/A
- Fundamental
- Price
- PRME $5.78
- ORGO $4.08
- Analyst Decision
- PRME Buy
- ORGO Buy
- Analyst Count
- PRME 6
- ORGO 3
- Target Price
- PRME $8.88
- ORGO $7.33
- AVG Volume (30 Days)
- PRME 3.8M
- ORGO 800.7K
- Earning Date
- PRME 11-11-2025
- ORGO 11-06-2025
- Dividend Yield
- PRME N/A
- ORGO N/A
- EPS Growth
- PRME N/A
- ORGO N/A
- EPS
- PRME N/A
- ORGO N/A
- Revenue
- PRME $4,961,000.00
- ORGO $429,531,000.00
- Revenue This Year
- PRME $179.58
- ORGO $2.51
- Revenue Next Year
- PRME N/A
- ORGO $25.45
- P/E Ratio
- PRME N/A
- ORGO N/A
- Revenue Growth
- PRME 739.42
- ORGO N/A
- 52 Week Low
- PRME $1.11
- ORGO $2.61
- 52 Week High
- PRME $6.94
- ORGO $6.71
- Technical
- Relative Strength Index (RSI)
- PRME 60.95
- ORGO 37.12
- Support Level
- PRME $4.87
- ORGO $4.12
- Resistance Level
- PRME $6.94
- ORGO $4.40
- Average True Range (ATR)
- PRME 0.49
- ORGO 0.24
- MACD
- PRME 0.07
- ORGO -0.06
- Stochastic Oscillator
- PRME 47.88
- ORGO 11.00
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.